Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Prosper AI›
Analysis
Prosper AI

Prosper AI

Series A

Prosper AI builds voice AI agents that automate healthcare operations across the patient journey.

HQ
New York, NY, US
Founded
2023
Accelerator
Y Combinator logoY CombinatorS23
Loading
Overview
Analysis
Compare
Fundraising
Employees
News

Contents

  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths
  5. 05Competitive Risks
  6. 06Pricing Strategy
  1. 01Executive Summary
  2. 02Products & Services
  3. 03Market Outlook
  4. 04Competitive Strengths
  5. 05Competitive Risks
  6. 06Pricing Strategy

Memo

Prosper AI, founded in 2023 by Xavier de Gracia and Josep Mingot, participated in Y Combinator S23 batch. The company raised a $5M seed in 2025 and a $30M Series A led by Andreessen Horowitz in June 2026.

The platform automates patient and payor calls including scheduling, benefits verification, billing, and prior authorization. It serves 60+ outpatient groups with 80+ EHR integrations and operates 24/7.

Product Overview

Prosper AI's voice agents handle both patient and payor phone calls, including scheduling, benefits verification, and patient billing. The platform is trusted by 60+ leading outpatient groups and EHR platforms.

The company claims its agents deliver 50%+ cost reduction, 20%+ revenue increase, and 99%+ QA accuracy. The platform offers 80+ integrations with EHRs and practice management systems and can be deployed in 3 weeks.

Market Outlook

The healthcare voice AI market is projected to grow significantly as healthcare providers seek to automate administrative tasks and reduce costs. Prosper AI targets the $450 billion spent annually on healthcare administration in the United States.

The company competes in a market that includes established players in medical documentation, patient engagement, and revenue cycle management. Prosper AI differentiates by focusing specifically on voice-first automation across the entire patient journey, from scheduling to billing.

Competitive Advantages

The healthcare voice AI market includes competitors such as Notable Health, Suki, and Ambience Healthcare. Prosper AI differentiates by focusing on the entire patient journey including scheduling, prior authorization, and revenue cycle operations.

The company targets the $450 billion spent annually on healthcare administration, with voice agents that operate 24/7 and integrate directly with existing practice management systems.

Competitive Disadvantages

Prosper AI's voice-first approach requires high-quality phone system integration and may face challenges with legacy healthcare IT infrastructure. Healthcare organizations with strict data residency requirements may need additional compliance verification.

The company competes against established players with deeper enterprise relationships and larger sales teams. Voice AI accuracy in complex medical scenarios remains an evolving challenge across the industry.

Pricing Strategy

Prosper AI does not publicly disclose specific pricing on its website. The platform targets healthcare providers and payors with enterprise-grade voice AI agents, suggesting a custom or usage-based pricing model.

The company claims its agents deliver 50%+ cost reduction and 20%+ revenue increase, indicating a value-based pricing approach aligned with customer ROI.